Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 8 Weeks of Treatment in Adult Patients With Newly Diagnosed Drug-Sensitive or Multi Drug-Resistant, Smear-Positive Pulmonary Tuberculosis
Brief Summary: The purpose of this study is to assess the mycobactericidal activity of the moxifloxacin plus PA-824 plus pyrazinamide regimen after 8 weeks of treatment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Moxifloxacin | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): 1, 2
B: Arm Label: Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg); Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (M), Drug: Pretomid (Pa), Drug: Pyrazinamide (Z) | Arm Label: Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg); Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (M), Drug: Pretomid (Pa), Drug: Pyrazinamide (Z) | Arm Label: Drug Sensitive: Rifafour; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rifafour | Arm Label: Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg); Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (M), Drug: Pretomid (Pa), Drug: Pyrazinamide (Z) | Intervention Type: DRUG; Name: Moxifloxacin (M); Assigned to Arm(s): Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg), Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg), Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | Intervention Type: DRUG; Name: Pretomid (Pa); Assigned to Arm(s): Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg), Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg), Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | Intervention Type: DRUG; Name: Pyrazinamide (Z); Assigned to Arm(s): Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg), Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg), Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | Intervention Type: DRUG; Name: Rifafour; Assigned to Arm(s): Drug Sensitive: Rifafour
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 4; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 5; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 6 (optional); Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Linezolid Cohort; Type: EXPERIMENTAL; Interventions: Drug: Linezolid | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 3 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 4 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 5 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 5 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 6 (optional) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 6 (optional) | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid Cohort
D: Arm Label: Regimen 1 - 2EHRZ/4HR (control regimen); Type: PLACEBO_COMPARATOR; Interventions: Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin | Arm Label: Regimen 2 - 2MHRZ/2MHR; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin | Arm Label: Regimen 3 - 2EMRZ/2MR; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin | Intervention Type: DRUG; Name: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin; Assigned to Arm(s): Regimen 1 - 2EHRZ/4HR (control regimen), Regimen 2 - 2MHRZ/2MHR, Regimen 3 - 2EMRZ/2MR

Answer: B